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Abstract
Breast augmentation and reconstruction procedures are among the most popular
plastic surgeries in the U.S. Opportunistic bacterial pathogens introduced during surgery
can lead to surgical site infections, capsular contractures, biofilm formation, and
lymphoma. To prevent these infections, an antibiotic solution containing Cefazolin,
Gentamicin, and Bacitracin (Adams’ Antibiotic Solution - AS) has traditionally been
used for irrigation. Due to antibiotic resistant pathogens and a debate over the efficacy of
irrigation by AS to reduce infections, alternatives must be found. This study considers the
use of the antiseptic chlorhexidine gluconate (CHG) as an alternative irrigation solution.
In vitro, we exposed pure cultures of six bacterial species known to cause infections
during this surgery to: AS, CHG, or a saline control (SAL) for one, two, or five minutes
in simulated breast “cavities” (test tubes). Viable plate counts carried out before and after
exposure allowed calculation of the percent survival for each bacterial species. Across all
time intervals, the average survival of CHG irrigated cultures was zero percent, though
some growth did occur with MRSA. Survival rates following SAL irrigation were
between 63.1-104%, and those following AS exposures were between 62.5-100%.
Student’s t-tests suggest that differential bacterial survival for CHG and SAL treatments
were significant (p < 0.05). However, comparison of bacterial survival in AS and SAL
treatments were not significant (p > 0.05) in most cases. These results suggest that use of
CHG for irrigation is more effective at killing potential pathogens than AS, and that AS is
little different from our controls. This finding has the potential to change the standard of
care in breast augmentation and reconstruction surgical procedures.
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Chapter 1
Background and Introduction
1.1

Literature Review
Breast augmentation and reconstruction procedures are among the most common

surgeries performed in the United States today, with over 300,000 breast augmentations
and over 100,000 reconstructions performed in 20173. Patients choose to have these
surgeries for a multitude of reasons. Each year, over 252,000 women are diagnosed with
breast cancer and must undergo full or partial mastectomies31. Prophylactic mastectomies
can be performed for women at high risk for developing breast cancer26. In both of these
cases, breast reconstruction can be used to improve the physical and emotional quality of
life for patients10. While the motivational factors for breast reconstruction typically
involve medically necessary mastectomy, women undergoing breast augmentation alone
cite a different multitude of reasons. Bilateral micromastia is a condition in which breasts
remain extremely underdeveloped following puberty. A similar condition called
unilateral micromastia, or breast asymmetry, results when there is very little or no breast
tissue on one side of the chest but developed breast tissue on the opposite side36. In the
face of societal pressures, women with these conditions often want to feel more “normal”
and indicate that these surgical procedures not only help them do that, but also that they
increase their confidence and sense of self43.
Despite the reason for choosing to endure either of these surgeries, other factors
such as cost must be considered. Costs for patients to consider include fees for anesthesia,
the surgical facility, medical tests, medications, specialized healing garments, and the
surgeon’s time; breast augmentation on average costs $3,718, and most health insurance
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plans will not cover any amount of that4. For breast reconstruction, costs vary and tend to
be higher, with a range of $6,422 to $40,015, as they depend on the surgeon’s expertise,
location, and the patient’s unique situation8. Women considering these surgeries must
also account for the need for future surgeries. Breast implants are not a permanent
solution, lasting about 10-20 years on average22. Typically, women with breast implants
will have to get them replaced once or twice in their lifetimes9.
Procedurally, breast augmentation and reconstruction differ slightly. Both
procedures involve creating a small incision through which to insert a prothesis. This
incision can be made in one of three areas (Figure 1.1-1), and the site for a particular
patient is decided based on the anatomy and desired outcome4.

Figure 1.1-1 Incision
placement for breast
augmentation and
reconstruction
procedures (American
Society of Plastic
Surgeons)

Reconstruction is usually a two-stage procedure. Following mastectomy, the patient has
no breast tissue and thus not enough skin to stretch over an implant. To create space
under the skin, an expander implant is used. A deflated implant is inserted under the
pectoralis major and serratus anterior muscles (Figure 1.1-2) and is gradually filled with
saline or air through a port over a course of 6-8 weeks (Figure 1.1-3). The expander
remains in the chest cavity for another 1-2 months to allow the skin to stretch before
another procedure replaces the expander with a more permanent prothesis8.
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Figure 1.1-3 Gradual filling of an expander
implant and its replacement by a more permanent
prosthesis (New England Journal of Medicine)

Figure 1.1-2 Use of an expander implant in the
creation of a breast cavity pocket (Johns Hopkins
University)

Breast augmentation tends to be a simpler procedure due to the presence of breast tissue
prior to the surgery. Shown in Figure 1.1-4, the first step after the initial incision is the
creation of a breast cavity pocket. To do this in a healthy breast, a sharp tool is used to
dissect the breast tissue. An implant can then be inserted into the cavity where tissue has
been separated.

Figure 1.1-4 Dissection of breast
tissue and the insertion of an
implant in breast augmentation
surgery (World Laparoscopy
Hospital)

Before and after insertion of the prosthesis in both reconstruction and augmentation
procedures, the pocket is irrigated with an antimicrobial solution and the small incision is
12

closed. Nearly all surgical openings are contaminated with bacteria during operation,
making it vital for the antimicrobial solution used in irrigation to be effective in a short
time period44.
When bacteria are introduced in these procedures, the resulting issues include
surgical site infections (SSI), capsular contracture, and lymphoma. SSI can be indicated
by redness at the incision site, mild swelling and irritation, or systemic infections and
death in severe cases. Usually, these are self-diagnosed and can be treated using
antibiotics. The incidence for SSI is around 12% for reconstruction procedures and varies
greatly for augmentations32. Capsular contractures are generally more severe as they
require removal of the implant and additional surgical correction. Contracture happens
when the patient’s immune system responds negatively to the foreign implant and begins
to “wall off” the implant with scar tissue. Tight scar tissue constricts the implant and
causes a misshapen breast and failed procedure (Figure 1.1-5). Further, the capsule
formed leaves the prosthesis prone to biofilm formation by any bacteria present in the
cavity following surgery. Antibiotics are unable to penetrate these biofilms, allowing
them to give rise to bacteremia7. Capsular contractures can occur as early as 4-6 weeks
after the initial surgery, with most capsules forming in the first six months following
surgery29. SSI typically occur within the first few months following the operation, but
some have been noted to appear after many years38. Capsular contracture is the most
common complication of these procedures, with an overall incidence rate of 10.6%16.
Considering the number of augmentation and reconstruction procedures performed in
2017, this equals approximately 43,000 patients.
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Figure 1.1-5 MRI of a capsular contracture (Right) (Indian Journal of Radiology and Imaging)

Another issue linked to breast implant surgery that has recently gained attention is
a potential link between these surgeries and lymphoma. An analysis of 173 breast implant
surgery cases suggested a link between breast implants and lymphoma5. The resulting
breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) can spread out of
the breast area and lead to significant illness and death. Further analysis of the
microbiome of BIA-ALCL sites revealed a higher concentration of Ralstonia pickettii
when compared to non-cancerous biofilms, indicating a potential cause for infection18.
BIA-ALCL is considered a novel issue facing women with breast implants, but Brody
explains the risk for developing lesions could be as high as 1 in 500,000 patients5. All of
these issues are aesthetically devastating for the patient and can be expensive to fix.
The principal way for plastic surgeons to avoid problems associated with bacterial
contamination of surgical cavities is the use of effective antimicrobial irrigation solutions.
The use of these solutions goes back as far as wound care does. The first solution to be
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widely marketed for use as wound lavage was an antiseptic called Dakin’s solution. It
was used very effectively to treat the wounds of soldiers in World War I12. Other
antiseptic solutions, such as castile soap, benzalkonium, and betadine (povidone-iodine)
were used consistently as irrigation before the discovery of antibiotics44.
Following the FDA contraindication of betadine (povidone-iodine) irrigation in
breast implant procedures, plastic surgeons had to evaluate and utilize different lavage
solutions1. In a study by William P. Adams, Jr., M.D., various antibiotics were tested in
vitro to mimic irrigation in an effort to discover a lavage solution that could replace
betadine. Adams et al. concluded a mixture of gentamicin, cefazolin, and bacitracin
provided coverage similar to betadine-containing solutions1. The efficacy of this solution
was later confirmed in vivo2. Despite this, questions concerning the clinical efficacy of
the triple-antibiotic solution (AS) as surgical lavage remain. Debate about the use of AS
centers around the fact that the three antibiotics are traditionally used topically. These
antibiotics are not used internally due to some types of toxicity they may cause.
Gentamicin can lead to irreversible ototoxicity or mild nephrotoxicity in up to 25% of
patients40, and bacitracin can be toxic when administered orally41. Cefazolin, when used
concurrently with an aminoglycoside like gentamicin, may increase the risk of
nephrotoxicity34. Each of these antibiotics is considered broad-spectrum, but the
combination may not be completely effective for the types of bacteria responsible for
breast-implant related issues. Gentamicin works by irreversibly binding to the 30S
subunit proteins and 16S rRNA of target cells, resulting in misread mRNA and
nonfunctional proteins15. Gentamicin primarily affects Gram-negative bacteria. Cefazolin
binds to penicillin-binding proteins in a bacterial cell membrane, inhibiting the final stage
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of peptidoglycan synthesis13, a critical component of bacterial cell walls. Under the right
conditions disruption of cell wall formation can induce cell lysis. It is used effectively
against Gram-positive Streptococci and Staphylococci, as these cells rely on thick
peptidoglycan layers in their cell walls. Bacitracin also affects cell wall synthesis for
Gram-positive cells. It interferes with the dephosphorylation of a specific molecule
needed to transport peptide building blocks of the cell wall from the cytoplasm to just
outside of the cell membrane, resulting in incomplete cell wall synthesis and cell death41.
Table 1.1-1 summarizes these antibiotics.
Table 1.1-1 Summary of Antibiotics in Adams’ AS
Agent

Mode of Action

Target

Binds to 30S subunit
Gentamicin

Gram Negative Bacteria
proteins/16S rRNA
Binds to penicillin-binding

Cefazolin

Gram Positive Bacteria
proteins
Dephosphorylation of

Bacitracin

Gram Positive Bacteria
peptide transport molecule

Use of AS for irrigation has inherent drawbacks. Overall, the mode of action for
these drugs is relatively slow, compared to certain antiseptics. If antibiotic irrigation
solutions are to be most effective, they should include antibiotics that may be taken
internally (e.g., cephalosporins), allowing prior applications of the antibiotic before
surgery to elevate the blood serum titer to levels that would prove antimicrobial within
the tissue. In that case the irrigation solution, using the same antibiotic mix, helps support
16

the action of the blood borne agent. This situation would lead to the greatest efficacy of
antibiotics as irrigation solutions. However, since the antibiotics used in the AS cannot be
given internally to build up a blood serum titer, the only exposure of potential pathogenic
bacteria to the antibiotics would be for the relatively short period of time they were used
during the actual surgery.
The antibiotic agents used in AS definitely take time to be effective. When used
for breast surgeries AS is essentially used topically, flushed through the breast cavity
with relatively short dwell times in the cavity. To be the most effective, gentamicin needs
30-60 minutes to reach peak serum concentrations following injection33, cefazolin
reaches its peak effectiveness after 1-2 hours45, and bacitracin is absorbed rapidly, but
only in intramuscular injection48. This time requirement makes it unlikely that rapid
surgical irrigation allows the drugs time to be fully effective. Gentamicin has a protein
binding incidence of less than 30% and may not be effective every time14. This is the
only antibiotic that targets Gram-negative bacteria among the three in AS, leaving a high
potential for infection by these microbes. Further, if biofilm growth occurs, penetration
by antibiotics is restricted7.
Another issue with the use of antibiotic solutions for surgical irrigation is the
growing incidence of antibiotic resistance among many pathogenic bacteria. Antibiotic
resistance among pathogens has been increasing since the widespread use of the drugs in
the 1940s, and an estimated 23,000 people die each year with infections by antibiotic
resistant bacteria6. One possible step to slowing antibiotic resistance is limiting the use of
these drugs, and instead considering antiseptic agents as alternative lavage solutions.
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Chlorhexidine gluconate (CHG) is an antiseptic that has antimicrobial activity
against a vast group of microbes. The antiseptic was discovered almost 60 years ago in
the United Kingdom, where it was commercially used as a disinfectant21. After it was
introduced into the United States in the 1970s, novel uses for CHG rapidly started
accumulating, with new chlorhexidine impregnated medical supplies and devices being
developed every few years until the present23. CHG is effective against Gram-positive
and Gram-negative bacteria, as well as fungi. It has also shown some efficiency against
spores, protozoa, and enveloped viruses11. CHG is a positively charged molecule which
binds to negatively charged cell or viral surfaces, destabilizing the cells or viruses,
interfering with osmosis, and causing leakage of internal components leading to cell or
viral death35. Uptake of CHG happens rapidly, in about 20 seconds25. While it is absorbed
rapidly by bacterial cells, CHG has limited absorption into blood serum or into interstitial
fluids, so toxicity to the organism being treated is limited46. The antiseptic has been found
to be able to provide antimicrobial activity for up to 48 hours after its application28. In its
soap form (Dyna-Hex 4) CHG also has lubricative properties as a surfactant and eases the
insertion of the prosthesis into the breast pocket, reducing the time it takes to complete
breast augmentation or reconstruction surgical procedures. The lubricative properties also
make it difficult for bacteria that end up on the prosthesis to bind to its surface and
colonize to form a biofilm28.
A survey was conducted by Dr. Mathew Epps of around 2,000 members of the
American Society of Plastic Surgeons about the type of lavage they use during breast
augmentation and reconstruction. About 17% of those surveyed responded, and of those,
a majority reported irrigating with Adams’ AS. With the efficacy debate surrounding AS
18

and the growing issue of antibiotic resistance, it is becoming more important for plastic
surgeons to seek out better irrigation solutions. This and additional research can aid in
establishing a more effective lavage than Adams’ AS for breast augmentation and
reconstruction procedures, and potentially for other types of surgery as well.

1.2 Introduction
In the Spring of 2017, David Levine, PT, PhD, DPT, Mark Brzezienski, MD, and
Mathew Epps, MD collaborated with Dr. Henry Spratt to evaluate the efficacy of AS and
CHG in reducing bacterial load during breast augmentation and reconstruction
procedures. Previous studies by Matthaiou et al.24, Brody et al.5, and personal experiences
of Dr. Epps allowed for the identification of several bacterial cultures frequently
associated with SSI, capsular contracture, and BIA-ALCL. These include three Grampositive cocci (Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus,
and Enterococcus faecalis) and four Gram-negative rods (Escherichia coli, Pseudomonas
aeruginosa, Acinetobacter baumannii, and Ralstonia pickettii). This in vitro study
focused on the antimicrobial efficiency of AS and CHG on each of these pure cultures by
mimicking surgical irrigation in the laboratory setting. The primary objectives for this
research are to gather data to either support or reject AS and CHG as surgical lavage
solutions and to compare the two in order to determine which solution is most effective.
We are also interested in evaluating whether the length of irrigation significantly affects
the percent survival of bacterial cells. The results of this study will provide wellestablished data on the effects of CHG and AS directly on the bacteria typically
associated with SSI, capsular contracture, and BIA-ALCL in breast augmentation and
reconstruction procedures. Further, since the CHG solution used in our laboratory mimics
19

the 0.05% CHG solution marketed to surgeons as Irrisept, our results will demonstrate
the efficacy of a much more cost-effective version of this 0.05% CHG. These results
could potentially have ramifications for all types of surgery if they show that CHG is at
least as effective as Adams’ AS in reducing bacterial load. The possibility of this solution
to replace AS in irrigation for breast augmentation and reconstruction procedures could
spread to other surgical settings. This would be a leap in the direction of reducing the
overuse of antibiotics and could serve as a step in slowing antibiotic resistance among
bacteria.
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Chapter 2
Materials and Methods

2.1 Materials and Cultures Used in This Study

2.1.1 Preparation of Bacterial Growth Media
To perform our experiments, we needed sterile brain heart infusion broth (BHIB),
tryptic soy broth (TSB) tubes, tryptic soy agar (TSA) plates and slants, and nutrient agar
(NA) tubes and slants. Refer to Table 2.1-1 for the specifications of materials used. To
make the TSB and BHIB tubes, clean and dry test tubes were filled with 10mL TSB or
BHIB and autoclaved to sterilize the solution. These were used to inoculate cultures prior
to each experiment. TSA and NA plates were made by thoroughly boiling and mixing a
TSA or NA solution in a 1L Erlenmeyer flask, which was then placed in the autoclave.
This mixture was aseptically poured into sterile petri dishes and allowed to solidify. TSA
and NA slants were made in a similar way, but the solution was pipetted into sterile test
tubes prior to autoclaving, and after removal from the autoclave the tubes were allowed
to solidify on a slanted surface. These were used to preserve and refresh pure cultures for
the duration of the study.

2.1.2 Preparation of Antibiotic and Antiseptic Solutions
For the saline control replicates, we used sealed bottles of 0.9% sodium chloride
irrigation (Table 2.1-1). Adams’ AS in the surgical setting contains 50k U bacitracin, 1g
cefazolin, and 80mg gentamicin in 500cc sterile saline. We scaled this down in the
laboratory to yield a 2mL solution containing 0.015g bacitracin, 0.024g cefazolin, and
21

0.048mL gentamicin in 1.952mL sterile saline. The CHG solution was diluted to 0.05%
by adding 0.15mL of the 4% chlorhexidine gluconate soap (Dyna-Hex 4) to 1.85mL
sterile saline.

Table 2.1-1 Materials Used in This Study
Material

Source/Brand

City, State

Tryptic Soy Agar

BD Difco #236920

Sparks, MD

Tryptic Soy Broth

BD Bacto #21825

Sparks, MD

Nutrient Agar

BD Difco #213000

Sparks, MD

Brain Heart Infusion Broth

BD BBL #299070

Sparks, MD

0.9% Sodium Chloride Irrigation USP

Braun Medical, Inc

Irvine, CA

4% Dyna-Hex 4 Chlorhexidine

Xttrium Laboratories, Inc.

Mount Prospect,

Gluconate

(NDC 0116-1061-01)

IL

Bacitracin for Injection, USP

Fresenius Kabi

Lake Zurich, IL

(NDC 63323-329-31)
Cefazolin for Injection, USP

Hospira, Inc

Lake Forest, IL

(NDC 0409-0805-01)
Gentamicin Sulfate Injection, USP

Hospira, Inc
(NDC 52584-207-03)
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Bastian, VA

2.1.3 Establishing Bacterial Cultures Used in This Study
Pure cultures of bacteria were inoculated at the beginning of the study onto TSA
or NA slants and incubated for 24-48 hours, depending on the speed of growth. Once
substantial growth was established, these were stored in a refrigerator for preservation.
Prior to each experiment, a sample of one culture was aseptically transferred into TSB or
BHIB using a heat-sterilized loop. The inoculated broth was placed in the incubator at
37˚C overnight. These overnight cultures (ONC) are what we used to pull samples from
for each experiment. Table 2.1-2 lists the bacterial cultures used.

Table 2.1-2 Bacterial Cultures Used in This Study
(All cultures below were obtained from UTC’s Bacterial Culture Collection
Bacterial Culture

Gram +/-

Source

Staphylococcus epidermidis

G+ coccus

ATCC #12228

Methicillin-resistant

G+ coccus

Environmental isolate from

Staphylococcus aureus

Erlanger NICU, UTC

(MRSA)
Enterococcus faecalis

CIDC Study 2016-2017
G+ coccus

ATCC #2921

Escherichia coli

G- rod

ATCC #25922

Pseudomonas aeruginosa

G- rod

ATCC #9027

Acinetobacter baumannii

G- rod

ATCC #19606

Ralstonia pickettii

G- rod

ATCC #27511
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2.2 Experimental Design
Variable conditions in this study included solution used and exposure time.
Irrigation solutions were tested at 1, 2, and 5 minutes to determine whether time spent
irrigating made a significant difference in killing efficacy. Each experiment began with a
serial dilution of the ONC of one of our experimental cultures as shown in Figure 2.2-1.
The serial dilution was conducted up to the 10-7 total dilution factor (TDF), and 0.1mL
samples from the three most diluted tubes were spread onto TSA plates to yield viable
plate counts at the 10-6, 10-7, and 10-8 TDF. These plate counts were used to calculate the
approximate number of colony forming units (cfu) per mL of liquid in the 10-3 tube,
which is the one used to inoculate our artificial cavity. The average density of bacterial
cells on normal skin is 105 cfu/cm2 30. The calculated cfu/mL in our ONC for each culture
was around 108, so using the 10-3 dilution allowed us to approach the accepted density of
bacterial cells on normal skin. This number gave us a baseline with which to compare our
bacterial counts after exposure to the irrigation solutions.
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Pre-Exposure Untreated Control

Post-Exposure
Experimental Treatment

Figure 2.2-1 Experimental design scheme used in this study

A 0.5mL aliquot from the 10-3 TDF was placed into one of six artificial cavities
(sterile test tubes, with three of the tubes being replicates for the sterile saline control and
three serving as replicates for the experimental condition of either AS or CHG). Then, a
0.1mL sample of one of the lavage solutions was aseptically transferred to the cavity.
Immediately after this transfer a timer was started to be able to precisely indicate 1, 2, or
5 minutes of exposure of the bacteria in the cavity to the control or experimental solution.
During this time, the mixture was thoroughly stirred using a vortex mixer. After this time,
a 0.1mL sample from the cavity was removed and rapidly diluted via a short serial
dilution into sterile saline to ensure that the experimental solution was quickly diluted to
well below its effective concentration. These dilutions of the cavity solution were
completed within 1 minute. The need for this rapid dilution of the experimental solutions
was exemplified in an early experiment with AS irrigation, where residual antibiotics
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were rapidly absorbed into the TSA plate, creating a zone of inhibition in the center of
the plate (Figures 2.2-2 and 2.2-3). TSA plates were spread from these dilutions yielding
plates to be counted at the 10-2, 10-3, and 10-4 TDF. All of the pre-exposure and postexposure plates were incubated at 37˚C for 24 hours. Plates were spread using spreading
rods that had been dipped in alcohol and flamed. This method ensures that neither the
alcohol nor heat are a factor in reducing bacterial numbers further. I utilized turntables
while spreading plates to ensure even growth of bacterial colonies. Viable plate counts
from the cavity solutions were used to calculate the number of colony forming units (cfu)
that survived irrigation conditions in the cavity and were compared against the number of
cells initially added to the cavity, allowing calculation of the percent survival of the cells
over the exposure time for the different cultures. The same procedure was followed for
each culture we obtained data for.

Figure 2.2-2 E. coli survival on TSB after AS
irrigation. At the 10-2 TDF, the 1-minute AS
irrigation was still having an effect on E. coli
survival.

Figure 2.2-3 MRSA survival on TSB after AS
irrigation. At the 10-2 TDF, the 1-minute AS
irrigation was still having an effect on MRSA
survival.
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2.3 Calculations and Statistical Analysis
To ultimately calculate percent survival, I first had to determine the number of
cfu/mL before and after exposure to the experimental solutions. I calculated the number
of cfu/mL in the ONC using the pre-exposure plate counts and used TDFs to calculate
the number of cfu/mL added to the cavity. To obtain the number of cfu received from
the cavity after exposure, I used the post-exposure plate counts in the same way. I
divided the post-exposure cfu by the pre-exposure cfu and multiplied by 100% to obtain
the raw percent survival of cells. Detailed sample calculations can be seen in Appendix
I.
Expected experimental variations in the quantities of bacteria in the ONCs from
day to day made it necessary to normalize our data to the saline controls. The first step
of this process is the determination of a normalizing factor. This is a number which
raises the average raw percent survival of the saline control replicates to 100%, or the
ideal survival. The normalizing factor is calculated by dividing 100 by the average
survival percentage of all three saline replicates. I multiplied this factor by the raw
percent survival for each replicate of CHG and AS. Finally, I averaged all three
replicates to obtain the reported percent survival for the designated culture, time
condition, and lavage solution.
When conducting statistical analyses, I used the normalized values of each
replicate for a treatment in a student’s t-test to compare the survival of the bacteria in the
experimental solutions with the saline control. GraphPad Software online statistical
calculator (www.graphpad.com/quickcalcs/ttest1/) was utilized for the unpaired t-tests. In
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addition to the comparisons with the saline controls I also compared whether the AS or
the CHG solutions were statistically similar. Lastly, in order to be considered statistically
significant the comparisons needed to yield a p value of < 0.05.
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Chapter 3
Results
Because all experiments were performed in triplicate, the reported percent
survival values are an average of the normalized values for each replicate. See Appendix
II for summary tables containing survival data and statistical treatments comparing
survival among the saline control, CHG, and AS within each time variable. See Appendix
III for statistical treatments comparing survival across exposure times for each culture
and irrigation solution.

3.1 Staphylococcus epidermidis
For exposure times of 1, 2, and 5 minutes, percent survival of S. epidermidis cells
exposed to CHG was 0.0% (±0.00). Cells exposed to Adams’ AS for 1 minute had an
average survival of 99.0% (±1.41). At 2 minutes, survival after AS irrigation decreased to
51.4% (±4.77), and it decreased further at a 5-minute irrigation to 39.9% (±5.20). AS was
no more efficient at killing bacteria than our sterile saline control irrigation (p>0.05) at
the 1-minute condition, but at 2 minutes and 5 minutes, AS was more effective than
saline (p<0.05). The differences in survival between CHG and saline, as well as CHG
and AS, were significant for each time condition (p<0.05). With AS irrigation, 2-minute
exposure was more effective than 1-minute exposure (p<0.05), but there was no
significant change in survival when exposure increased from 2 minutes to 5 minutes
(Figure 3.1-1).
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Percent Survival

Figure 3.1-1
A
99
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B
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39.9

2-Minute

5-Minute

Exposure Time
AS
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ERROR
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1.41
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4.77
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5.20

Figure 3.1-1 S. epidermidis survival after different exposure times (1, 2, and 5 min) to AS.
Normalized to survival in saline (Mean values presented, n=3). A represents no statistical
difference from 1-minute exposure, B represents difference from 1-minute exposure, and C
represents difference from 1-minute exposure and one other condition.
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3.2 MRSA
CHG was more effective at killing MRSA than saline and AS at all time intervals,
but it did not kill all cells (Figure 3.2-1). After CHG irrigation for 1 minute, average
survival was 9.24% (±0.64). After 2 minutes survival was 23.28% (±3.88), and after 5
minutes it was 15.48% (±1.17). The difference in survival from 1-minute CHG irrigation
to 2-minute CHG irrigation was substantial (p<0.05), but 2-minute and 5-minute CHG
irrigation were similar (p>0.05). Irrigation by AS yielded percent survivals of 98.73%
(±1.34) after 1 minute, 89.40% (±8.97) after 2 minutes, and 45.17% (±2.26) after 5
minutes. AS irrigation resulted in significant bacterial reduction compared to saline only
at the 5-minute irrigation condition. Statistical comparison among AS-irrigated replicates
at different time conditions indicated significance again only after 5 minutes.

Figure 3.2-1
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Figure 3.2-1 MRSA survival after exposure to CHG and AS for different dwell times. Normalized to
survival in saline (Mean values presented, ±1SE, n=3, significantly different from saline, t-test @
p<0.05 = *). Irrigation by CHG did not kill all MRSA cells, but significant reduction occurred. AS only
reduced a substantial number of cells when used for a 5-minute irrigation time.
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3.3 Enterococcus faecalis
E. faecalis samples irrigated with CHG for 1 minute and for 5 minutes had
survival of 0.00% (±0.00). After a 2-minute irrigation by CHG, survival was 0.74%
(±0.60). This minor fluctuation across time intervals was not significant (p>0.05), while
the bacterial reduction exhibited by CHG when compared to saline was very significant
(p<0.05). Following AS-irrigation for 1 minute, average survival was 87.18% (±8.19).
After 2-minute irrigation with AS, survival was 88.60 (±10.32), and after 5-minute
irrigation, it was 116.3 (±4.96). Percent survival after irrigation with AS was not any
different when compared to the saline control, and further, it did not change when
exposure time was varied.

Figure 3.3-1
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Figure 3.3-1 E. faecalis survival after different exposure times (1, 2, and 5 min) to AS and saline.
Normalized to survival in saline (Mean values presented, ±1SE, n=3)
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3.4 Escherichia coli
Across all time conditions, CHG killed all E. coli cells. Percent survival under AS
irrigation varied. At 1 minute, survival was normalized at 127.0% (±7.68). At 2 minutes,
the survival rate decreased to 70.23% (±3.66), and at 5 minutes it increased to 97.39%
(±7.47). Irrigation by AS was only different from saline at a two-minute exposure time
(Figure 3.4-1). The efficacy of 2-minute AS irrigation was confirmed in a comparison
looking at survival across time variables within the condition of AS. CHG was
significantly more effective than both the control and AS at each time condition.

Figure 3.4-1
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Figure 3.4-1 E. coli survival after different exposure times (1, 2, and 5 min) to AS. Normalized to
survival in saline (Mean values presented, ±1SE, n=3, significantly different from saline, t-test @
p<0.05 = *). AS irrigation for 2 minutes resulted in significant reduction of E. coli.
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3.5 Pseudomonas aeruginosa
CHG irrigation was completely effective at each time condition in killing P.
aeruginosa. Irrigation with AS for 1 minute yielded 85.1% (±2.76) survival. At 2
minutes, survival was calculated at 117.8% (±3.82). A 5-minute irrigation yielded
105.2% (±1.13) survival. Compared to saline, AS irrigation did not result in significant
differences in bacterial survival at any exposure time. Longer exposure to AS actually
resulted in a higher percent survival, with the 2-minute and 5-minute irrigated replicates
generally having a higher survival than the 1-minute replicates (p<0.05) (Figure 3.5-1).

Figure 3.5-1
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Figure 3.5-1 P. aeruginosa survival after different exposure times (1, 2, and 5 min) to AS. Normalized to
survival in saline (Mean values presented, ±1SE, n=3, significantly different from 1-minute irrigation by
AS, t-test @ p<0.05 = *)
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3.6 Acinetobacter baumannii
Irrigation by CHG was 100% effective at killing A. baumannii in each replicate
and at each time condition. Following AS irrigation, survival after 1 minute was 103.0%
(±6.35), survival after 2 minutes was 99.72 (±1.14), and survival after 5 minutes was
123.1 (±10.1). None of the differences in survival across time conditions were significant,
nor was irrigation by AS any more effective than that by sterile saline.

Figure 3.6-1
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Figure 3.6-1 A. baumannii survival after different exposure times (1, 2, and 5 min) to AS and saline.
Normalized to survival in saline (Mean values presented, ±1SE, n=3). A. baumannii did not have
differential survival when exposed to AS vs. sterile saline.
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3.7 Ralstonia pickettii
Experiments with Ralstonia pickettii were unsuccessful with the design scheme
used for all of the other cultures. ATCC recommended growing R. pickettii on NA rather
than TSA. There was plenty of growth to inoculate NA slants and establish a working
stock. However, when I inoculated NB for an ONC, I achieved very little to no growth
(Figure 3.7-1), and the initial serial dilution reduced cells below countable numbers. To
obtain more growth, I inoculated R. pickettii in BHIB and incubated it at 37˚C overnight.
Growth in BHIB was plentiful (Figure 3.7-2).

R. pickettii

Figure 3.7-1ONC
Ralstonia
(NB) pickettii growth in NB
(left) compared to sterile NB (right)

Figure 3.7-2 Ralstonia pickettii growth in BHIB

Though there was significant growth in the BHIB, I still modified the
experimental scheme slightly to ensure statistically valid colony counts and calculations.
To do this, I started the initial serial dilution with two 1:10 dilutions rather than a 1:100
dilution followed by a 1:10 dilution. Further, I spread NA plates at every TDF possible so
that I would not miss any statistically valid counts. Another change made was the
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inoculation of the artificial “cavity” with cells diluted to a 10-2 TDF rather than the 10-3
used with the other cultures. Despite these changes, R. pickettii still did not grow on any
of the pre- or post-exposure plates spread during the experiments for 1, 2, or 5-minute
irrigation times.

3.8 Comparisons Across Cultures
In some cases, AS significantly reduced bacterial counts (Figure 3.8-1). None of
the cultures in this study were significantly affected by AS-irrigation for 1 minute.
Enterococcus faecalis, Pseudomonas aeruginosa, and Acinetobacter baumannii were not
reduced by AS lavage at any of the three irrigation times. Staphylococcus epidermidis
was the only culture to exhibit a negative correlation between irrigation time and percent
survival of cells (Figure 3.8-2).

Figure 3.8-1
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Figure 3.8-1 Bacterial survival of all cultures after different exposure times (1, 2, and 5 min) to AS.
Normalized to survival in saline (Mean values presented, ±1SE, n=3, significantly different from saline, t-test
@ p<0.05 = *). Irrigation by AS significantly reduced bacterial load of some cultures at certain exposure times.
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Figure 3.8-2
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Table 3.8-1 Summary of Statistical Significance from Saline (indicated by p-value<0.05 = *)

Experimental Condition
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P.
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1 Min
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Irrigation

2 Min
5 Min
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*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*
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Chapter 4
Discussion
4.1 Significance of Results
SSI, capsular contracture, and BIA-ALCL are all devastating complications for
women undergoing breast augmentation or reconstruction procedures. Not only do they
cause pain and potentially failed procedures, they are costly to remedy. Reducing the
incidence of these issues starts with reducing the presence of the bacteria responsible for
them. The lavage solution currently being used by many surgeons in these procedures,
Adams’ AS may not be as effective at killing bacteria as previous studies suggest. To be
antimicrobial in the tissue, antibiotics should be given internally ahead of time and
allowed time to build up a titer in the blood serum of the patient. Surgical irrigation by
Adams’ AS, which contains antibiotics that cannot be given internally does not allow this
build-up of antibiotic in the interstitial fluid and the antimicrobial activity is not as
effective. In this in vitro study, Adams’ AS was effective only for S. epidermidis, MRSA,
and E. coli and only at a minimum of 2 minutes irrigation time. MRSA was not affected
until 5 minutes of exposure. AS irrigation was not more effective at reducing cell counts
than saline at any of the three exposure times for Enterococcus faecalis, Pseudomonas
aeruginosa, or Acinetobacter baumannii. It is important to note that in the survey
conducted by Dr. Epps of plastic surgeons who perform these procedures routinely,
respondents were asked about the amount of time spent irrigating and what irrigation
solution they used. The surgeons who reported using Adam’s AS indicated that they
irrigated for 30 seconds. Our study shows that Adam’s AS irrigation alone simply is not
39

effective at killing these bacteria associated with SSI, capsular contracture, and BIAALCL at an exposure time of less than two minutes.
Bacterial response to CHG was much stronger. CHG was effective for every
bacterium tested at the shortest irrigation time (1 minute, note that for R. pickettii, our
data is incomplete, and thus inconclusive), suggesting CHG could be an alternative to
lavage by AS. MRSA was the only culture to survive this irrigation, though bacterial
counts were still very reduced. This may be a result of how CHG works in relation to
resistant S. aureus. CHG’s mechanism of action relies on the negatively charged bacterial
cell wall to attract its own positively charged molecules. In strains of S. aureus that have
become resistant to antibiotics, mutated operons are expressed, and many of these
increase positive surface charge of the bacterial cell27. This could reduce the affinity for
bacterial cells by CHG and reduce its efficacy.
Using Adam’s AS for lavage poses a few issues. Since the antibiotics used cannot
be delivered internally, there is no titer of the drugs in the patient’s interstitial fluid. As a
result, the only exposure bacterial cells get to the antibiotics is for the actual dwell time
of the lavage solution. This concern is not a factor when you consider antiseptics, which
are effective on contact and do not need to build any sort of titer in the body.
With the ever-present threat of antibiotic resistant bacteria increasing, it is
becoming more important to find ways to reduce the use of these drugs. Finding effective
alternatives wherever possible is the first step we can take in slowing down this problem.
Our data suggests that CHG is an effective alternative lavage solution, though additional
research will be needed to implement it in the clinical setting. These findings and those of
future research could be used to establish CHG as a new standard in irrigation for breast
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augmentations and reconstructions as well as countless other surgeries and potentially
reduce the occurrences of SSI, capsular contracture, and BIA-ALCL. CHG is also useful
in the treatment of biofilms. Biofilm cells can be eliminated by 0.05% chlorhexidine
gluconate in one minute42. CHG in its soap form (Dyna-Hex 4) compared to its aqueous
form (Irrisept) has the added benefit of being a detergent. Detergents characteristically
have molecules with a hydrophilic head and a hydrophobic tail17. Because of this, they
are able to break apart the lipid-containing bacterial cell walls in biofilms and the
membrane proteins within39. Antibiotics have a difficult time penetrating an established
biofilm7, so this advantage by CHG could prove useful in the clinical setting.

4.2 Cost Efficiency
The cost of Adams’ AS per surgery ranges between $2 to $154, depending on the
availability of generic antibiotics2. A pre-made aqueous 0.05% CHG solution branded as
Irrisept (FDA K080779) can be purchased by surgeons at $60 per use19. The solution
used in our lab is made from a 4% CHG stock soap called Dyna-Hex 4, which we dilute
precisely to 0.05%. This Dyna-Hex 4 can be purchased for $250 per gallon. With the
process of diluting the 4% stock solution, one gallon can be used for many applications,
putting the cost at pennies per surgery. Even at the lowest price end for AS, our proposed
method of precisely diluting concentrated CHG costs far less, which is important for the
patients receiving these surgeries and for the surgeons performing them.

41

Chapter 5
Limitations and Future Research
Although this study was conducted following rigorous protocols to yield a high
degree of accuracy, potential limitations in the application of the results presented here
exist. This was an in vitro study, so the results of the study cannot be used directly to say
that irrigation by CHG rather than Adams’ AS will reduce the incidence of SSI, capsular
contracture, or BIA-ALCL in breast augmentation and reconstruction patients. To make
such a sweeping assumption would require additional research, such as a clinical study to
compare the incidence of these problems linked to specific types of irrigation. However,
the data presented here does provide strong, suggestive evidence that CHG irrigation has
the potential to reduce bacterial presence when used in the time-frame of these actual
surgical procedures.
One of our objectives for this study was determining if the duration of irrigation
made a significant impact on the efficacy of the lavage solution. We saw a clear
correlation between exposure time and killing efficiency with S. epidermidis, but not
necessarily for the other cultures in the study. Further studies attempting to evaluate time
as a factor may need to include a greater number of exposure times, possibly even an
option for leaving CHG in the breast cavity after the incisions are closed. If the CHG
solution is left in the breast cavity, then studies of potential toxicity towards surrounding
tissues must be conducted in vitro if possible.
To determine if leaving CHG in the breast cavity post-operatively has a toxic
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effect, future students might work with breast fibroblasts as a model tissue type in a labbased toxicity study. Different types of fibroblasts are available from culture collections,
and studies may compare their survival characteristics when exposed to concentrations of
CHG with fibroblasts collected from patients during these surgeries, something that
would require additional Institutional Review Board approval. The purpose of these
studies would be to determine whether any toxicity occurs so that CHG may be left in the
cavity indefinitely. In the surgical setting, this means irrigating with CHG and leaving the
solution inside of the breast pocket after closure of the incision, instead of rinsing it out
with saline. This way, the substantive properties of CHG will allow it to continue to have
antimicrobial effects on the area during healing, potentially reducing the ability of any
pathogens that may survive the initial irrigation to colonize the prothesis and cause
infection and biofilm formation.
Additional bacteria and yeasts linked to SSI, capsular contracture, and BIAALCL were identified by Dr. Epps and will be involved in future studies. These include
Staphylococcus aureus, Staphylococcus lugdunensis, Klebsiella pneumonia,
Propionibacterium acnes, Candida tropicalis, and Candida albicans. As a result of the
previously mentioned survey conducted by Epps, 31 different lavage solutions containing
various mixtures of antibiotics and antiseptics were discovered as being currently used by
plastic surgeons performing these procedures. These will also be evaluated to determine
killing efficacy of different bacterial cultures in vitro. Ultimately, the goal of future
studies is to provide evidence that would support the best irrigation solution and
conditions of surgical irrigation that would lead to a reduction in complications from not
only breast augmentation or reconstruction surgeries, but possibly other surgeries as well.
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Appendix I
Sample Calculations

*TNTC indicates growth too numerous to count

CFU Added to Cavity
[Pre-exposure colony count]/TDF = cfu/mL in ONC

101/10-7 = 1010000000

[cfu/mL ONC]*10-3 = cfu/mL added to cavity
1010000

1,010,000,000*10-3 =

[cfu/mL added to cavity]/2 = cfu added to cavity

1010000/2 = 505000

Average CFU Received from Cavity
Repeat for each replicate.
[Post-exposure colony count]/TDF = cfu/ml received

69/10-4 = 690000

[cfu/mL received]/2 = cfu received

690000/2 = 345000

Raw Percent Survival
Repeat for each replicate.
[cfu received from cavity]/[cfu added to cavity] * 100% = Raw Percent Survival
345000/505000 * 100% = 68.32%
Normalizing Values
100/[Average Saline Percent Survival] = Normalizing Factor = 100/90.1
Repeat the following for each replicate of CHG and AS
[Raw percent survival]*[100/90.1] = Normalized percent survival
68.32*[100/90.1] = 75.83
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Appendix II
Survival Data and Statistical Analyses at Different Dwell
Times
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Appendix III
Survival Data and Statistical Analyses Across Dwell Times
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